Netarsudil

Evidence Level: N/A

Predicted Indications: 0

Netarsudil

Pharmacist Assessment Report

Netarsudil: Known uses and market status in India

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Netarsudil, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The known uses are listed below with their sources.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	2
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data
Number of Listed Products	3 (valid: 3)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
glaucoma	licence in another country; approved indication: open-angle glaucoma

Indication	Approved category
primary hereditary glaucoma	glaucoma

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence	Product	Dosage form	Status
151923	Netasudil Eye Drop	bottle of 2.5 ml Ophthalmic Solution	Valid
184587	Raiki 0.02% Eye Drop	bottle of 3 ml Eye Drop	Valid
150621	Netalo Eye Drop	bottle of 3 ml Ophthalmic Solution	Valid

Safety Considerations

Drug Interactions: The data show pharmacological target interactions with ROCK1 and ROCK2, consistent with the drug’s mechanism. No drug-drug interactions with specific agents were recorded.
Safety signals in the literature (case reports): epithelial keratopathy, conjunctival fragility (including intraoperative and postoperative complications), punctal stenosis or closure, verticillata and honeycomb hypertrophy.

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.